Axsome Therapeutics, Inc. (NASDAQ: AXSM) — A Genuinely De-Risked CNS Franchise, Now Priced for the $8 Billion It Hasn’t Sold Yet

Report date: 2026-07-04. Reference price: $244.31 (2026-07-02 close). Market cap ~$12.4B; enterprise value ~$12.3B.

Independent equity research — for general information only; not investment advice.

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice. The analysis that follows takes no position and carries no price target; only this fenced block expresses a view.

Verdict: HOLD / accumulate-on-weakness. Not a short. Medium conviction. Axsome is the best-executing commercial-stage neuroscience company of this cycle, and the April 30, 2026 FDA approval of Auvelity for Alzheimer’s-disease agitation turned its single biggest binary into a real, launched second indication. The business is genuinely better than the skeptics who called it “two generics in a capsule” allowed. But at $244 — a near-all-time-high, above the ~$235 average sell-side price target, at ~17.4x trailing sales and ~5–6x the CNS peer-median EV/Sales — the stock already discounts a $4.5–5.5B durable franchise, roughly 7x the current run-rate, and management’s $8B Auvelity-alone peak claim is doing a lot of the lifting. My reverse-DCF says today’s EV is fair on the base case and only cheap on the bull case; you are paying full price for flawless agitation uptake against entrenched Rexulti, for margin conversion that has not yet begun (Q1-26 operating losses actually widened to −$62.8M), and for an IP estate built on two off-patent molecules. Framing: a high-quality, high-momentum compounder at a demanding price — quality-at-the-wrong-entry, not a mispricing. The tape confirms it: RS-12m +137%, a growth-biotech factor cohort (DNLI/IDYA/ARKK), and a one-directional insider tape — every 2026 Form 4 is an exercise-and-sell, zero open-market buys, the founder-CEO monetizing ~$24M into the run.

Directional zone (my view, not a target): new money is better served waiting for the 200-day area (~$180s) — where EV implies ~$4B of franchise revenue and you buy closer to the base case than the bull — with genuine value emerging nearer $150. At $255-ATH prices you are underwriting the bull. It is not a short: the franchise is real, gross margins ~92%, the pipeline is a genuine stack of shots on goal, momentum is violent, and a large-pharma takeout is plausible. Catchy tag: “the best drug launch in neuroscience, priced as if the $8 billion is already in the bottle.” Conviction: medium. Flips bullish on two or three quarters of agitation TRx tracking above the Rexulti launch benchmark plus the operating-margin inflection (losses turning toward profit). Flips bearish on decelerating Auvelity TRx, a soft agitation launch, or a Paragraph IV / Orange Book breach that pulls the generic date forward.

📈 Stock Price Action — Five-Year Event Map

Over the trailing ~60 months AXSM round-tripped from an abandoned FDA-overhang name to a near-all-time-high franchise compounder. It fell ~70% from an early-2021 high (~$68) to a 5-year low of $19.91 (Aug 19, 2021) the day the FDA disclosed “deficiencies that preclude labeling” on AXS-05 — then re-rated roughly 12x to an all-time high of $255.17 (June 2026) across the Auvelity approval-and-launch cycle. It trades at $244.31, only −4.3% off the ATH, inside a 52-week range of $100.39–$255.17. Price moves are FACT; the attributed drivers are INTERPRETATION. (Source: AZI 5-year adjusted price CSV; cross-referenced to 8-K/earnings/FDA events.)

Cycle narrative. (1) AXSM entered 2021 as a richly valued pre-revenue CNS name; the Aug 9, 2021 FDA “deficiencies” disclosure on AXS-05 — the depression drug that was essentially all the equity value — halved it in a day. (2) The overhang, the biotech bear market, and a migraine-asset stumble drove it to a ~$20 trough, an option on FDA resolution. (3) Sentiment inverted mid-2022: a +51% day as the path de-risked, capped by the Auvelity MDD approval (Aug 19, 2022, +40%) — the day AXSM became a commercial company. (4) Q4-2022 extended the re-rate on early launch traction. (5) 2023–2024 were a two-year consolidation ($60–$98) as scripts and Sunosi compounded without a new catalyst. (6) The Symbravo migraine approval (Jan 30, 2025) re-energized the tape, though the spike round-tripped. (7) H2-2025 delivered the decisive +83% leg on sNDA acceptance and 65% revenue growth. (8) 2026 paid off — the agitation approval (Apr 30, 2026), the $8B peak claim, and a June launch carried AXSM to a $255 ATH, −4.3% below which it sits today. This is price history, not a call — the opportunity judgment lives in Claude’s Take above.

1. Executive Summary

Axsome Therapeutics is a founder-led, New York-based commercial-stage neuroscience company whose economic engine is a portfolio of branded, patent-protected reformulations and combinations of largely off-patent molecules, sold through its own specialty salesforce into psychiatry, neurology, sleep, and — newly — dementia care. It has three marketed products: Auvelity (dextromethorphan-bupropion, for major depressive disorder and, since April 30, 2026, Alzheimer’s-disease agitation); Sunosi (solriamfetol, for excessive daytime sleepiness); and Symbravo (meloxicam-rizatriptan, for acute migraine). Revenue scaled from ~$0 in 2021 to $638.5M in FY2025 (+66%), with Q1-26 at $191.2M (+57% YoY). Auvelity is ~79% of revenue — this is, in substance, a single-product story with two adjuncts.

The business is genuinely good in ways skeptics under-rate. Gross margins run ~92%. Growth is all-organic, launch-driven, and among the best-executing CNS launches of the cycle — Auvelity grew +74% in FY25, its third full year. The commercial machine is real: ~60,000 cumulative prescribers, 86% covered lives, a salesforce doubling toward ~630 reps. The IP is unusually long-dated (Auvelity protected to 2038/2039 under the Teva settlement; Sunosi to 2040) — this is not a near-term patent-cliff story. And two of the most-hyped novel-mechanism MDD challengers (J&J’s aticaprant, Neumora’s navacaprant) failed Phase 3 in 2025–26, thinning the forward competitive set.

The problem is price, not quality. At EV ~$12.3B / ~17.4x trailing sales / ~5–6x the CNS peer-median EV/Sales, the market underwrites roughly $4.5–5.5B of durable franchise revenue realized within ~5 years — about 7x the current run-rate — and roughly 55–70% of management’s aggressive $8B Auvelity-alone peak claim spread across the portfolio. Valued like Neurocrine today, EV would be ~$2.8B; ~77% of the current EV is franchise-not-yet-built optionality. Meanwhile the cost side is running hot: SG&A hit ~89% of revenue in FY25 and Q1-26 operating losses widened to −$62.8M as the agitation launch, national DTC, and salesforce expansion loaded in. Stock-based compensation of ~$94M in FY25 roughly equals the year’s cash burn — the burn is effectively paid in dilution (share count 37.6M → 51.4M since 2021). And every 2026 insider transaction is a planned exercise-and-sell — zero open-market purchases — with the founder-CEO monetizing ~$24M near the highs.

The moat is real but shallow in kind: long-dated patents plus an increasingly capable commercial platform, over molecules that are individually generic. The durability is in duration, not in structure. The thesis tension is entirely valuation and timing — the pace of margin conversion, the agitation launch curve versus entrenched Rexulti, and whether a stock priced for a 60–70% realization of an $8B narrative can absorb even an in-line quarter. No recommendation and no price target appear below; the analysis that follows is position-free.

2. Business Overview

What it is. Axsome (founded 2012, IPO November 2015, 712 employees) develops and commercializes novel central-nervous-system therapeutics in the United States. Its model is distinctive and worth stating plainly: rather than discovering new molecular entities, Axsome builds proprietary combinations and reformulations of well-characterized, largely off-patent compounds, wraps them in composition/formulation patents and clinical data, secures FDA approval on differentiated efficacy or tolerability, and sells them through a purpose-built specialty salesforce. The result is branded specialty-pharma economics (~92% gross margin) on a lower-risk, faster development path than de-novo drug discovery — at the cost of a structurally weaker moat.

The three marketed products (FACT):

Sources: Axsome FY2025 results (GlobeNewswire, 2026-02-23); Q1-2026 results (2026-05-04). Accessed 2026-07-04.

Revenue concentration. Auvelity is ~79% of FY25 revenue and rising (Q1-26: $153.2M of $191.2M = 80%). Sunosi is a cash-generative, slow-growth acquired asset; Symbravo is a nascent, tiny launch. Any AXSM thesis is 80%+ a thesis on Auvelity — a concentration risk the diversified-sounding “three products, six pipeline candidates, ten indications” framing partly obscures.

How it makes money. Net revenue = gross scripts less substantial gross-to-net (GTN) deductions — rebates, chargebacks, co-pay support — which in psychiatry are heavy (Auvelity/Sunosi GTN discounts ran “low-to-mid-50s%” in Q1-26; Symbravo, early in launch, ran high-70s%). Below the ~92% gross line sits large SG&A (DTC advertising + salesforce) and heavy R&D. The economics are excellent at the gross level; the open question is whether commercial spend scales into profit.

Commercial infrastructure — the second pillar. This is the asset the market and skeptics both under-weight. Axsome has built a genuine CNS commercial engine: ~60,000 cumulative unique Auvelity prescribers since launch (5,500 new in Q1-26 alone), 86% of covered lives (78% commercial, 100% government), contracts with all three major GPOs, a national DTC campaign, and a salesforce expanding to ~630 reps to reach ~68,000 HCP targets across primary care, psychiatry, neurology, and geriatrics ahead of the June-2026 agitation launch (Q1-26 call; GlobeNewswire Q3-25). More on why this, not any single patent, is the durable asset, discussed below.

Pipeline (recurring shots on goal, all CNS-adjacent, all leveraging the same platform): AXS-05 for Alzheimer’s agitation (approved Apr 2026); AXS-12 (reboxetine) for narcolepsy/cataplexy (NDA submitted 2026); AXS-14 (esreboxetine) for fibromyalgia (Phase 3); solriamfetol label expansions (MDD, ADHD, shift-work disorder via the FOCUS trials, binge-eating); AXS-05 for smoking cessation (Duke collaboration); a GABA-A positive-allosteric-modulator (AXS-17 / AZD7325, licensed from AstraZeneca Nov 2025) for epilepsy; and AXS-20, a PDE10A inhibitor for schizophrenia/Tourette. The strategic logic is coherent: reuse one commercial platform across many CNS indications.

Verdict. A well-run, ~92%-gross-margin specialty-CNS company with a real and scaling commercial platform, but a revenue base that is ~80% one drug. The business quality is higher than the “two generics in a capsule” caricature; the concentration risk is higher than the multi-product framing implies.

3. Industry Dynamics

Structure — a “generic ocean with branded islands.” CNS/psychiatry is a large, chronic-disease, high-prevalence market with a peculiar shape: enormous patient populations sit on cheap generics (SSRIs, SNRIs, modafinil, triptans — pennies per script), punctuated by branded novel-mechanism entrants that must justify a large price premium on incremental efficacy or tolerability. It is a good market for a differentiated brand while patent-protected, brutal at loss of exclusivity, and permanently pressured by payers who default to generics. Applying the Greenwald lens: the industry offers no inherent customer captivity or economies of scale — profitability accrues only to whoever holds a time-boxed regulatory/patent barrier over a genuinely differentiated asset.

MDD / antidepressants (Auvelity’s core TAM). The largest psychiatric market, but its backbone is generic SSRI/SNRI/NDRI therapy. Branded competition lives in adjunct and treatment-resistant niches: Spravato (esketamine, J&J — REMS-restricted, in-office, >$1B franchise, a different treatment setting than oral Auvelity); Caplyta (lumateperone, now J&J/Intra-Cellular — adjunct MDD approved 2025); adjunct antipsychotics (Rexulti/Abilify, under generic aripiprazole pressure); and Zurzuvae (zuranolone, Sage/Biogen — approved only for postpartum depression; the MDD program failed). Critically, the two most-hyped next-gen oral MDD challengers flamed out: J&J’s aticaprant (kappa-opioid antagonist) was discontinued in March 2025 after the Phase 3 VENTURA program failed, and Neumora’s navacaprant went 0-for-3 in Phase 3 by mid-2026 (pharmaphorum 2025; TechTimes 2026-06-16). Auvelity — the first oral NMDA-antagonist antidepressant, with ~1-week onset versus SSRIs’ 4–6-week lag — now faces a thinner forward competitive set than it did two years ago. That is a genuine tailwind (FACT).

Alzheimer’s-disease agitation (the new TAM — the crux). Agitation affects a majority of Alzheimer’s patients (estimates up to ~76%). Before 2023 there was zero approved therapy. Today there are two: Rexulti (brexpiprazole, Otsuka/Lundbeck), approved May 2023, already a >$1.2B franchise and growing (~7–8% CAGR toward ~$2.8B by 2033) — but an antipsychotic carrying a boxed warning for increased mortality in elderly dementia patients — and, since April 30, 2026, Auvelity, the first and only non-antipsychotic for the indication. The clean-label differentiation into a large, underserved, growing pool is the single biggest structural TAM expansion in the AXSM story (Psychiatric Times 2026; GlobeNewswire 2026-04-30). Its magnitude in practice is the open question.

Narcolepsy / EDS (Sunosi’s TAM). ~$3.5B (2022) growing to ~$5.9B (2030). Dominated by Jazz’s oxybate franchise (Xyrem → Xywav), protected by a REMS-controlled distribution monopoly — a genuine regulatory moat. The wake-promoting layer beneath it is generic modafinil/armodafinil (a cheap floor) plus Wakix (pitolisant, Harmony — the key growing competitor) and Sunosi itself. Sunosi is a ~#3 EDS agent in a crowded, generic-anchored niche — hence its modest $300–500M peak framing.

Acute migraine (Symbravo’s TAM). ~$6.8B (2024) → ~$13.3B (2030), ~11% CAGR, now gepant-dominated: Nurtec ODT (Pfizer), Ubrelvy and Qulipta (AbbVie), Zavzpret (Pfizer), plus generic triptans as the cheap floor. Symbravo shows strong network-meta-analysis efficacy and works in gepant/triptan non-responders — but both its components are cheap generics, so KOLs flag payer resistance to brand pricing. A crowded field backed by AbbVie and Pfizer’s commercial firepower.

Regulatory / reimbursement. Three structural factors matter. (1) IRA Medicare price negotiation is the real overhang: Auvelity, a small-molecule Part D drug approved October 2022, becomes eligible for CMS “selection” ~9 years post-approval, plausibly yielding a negotiated price effective ~2032–2033 — well before its 2038–39 patent LOE. This caps the back half of the peak-sales runway on the largest product (INTERPRETATION on exact timing). (2) PBM/formulary step-edits: the entire model depends on winning formulary tiers versus generics; the 86%-covered-lives win is hard-fought and reversible. (3) DTC advertising is central to psychiatry brands, and is a primary driver of the SG&A surge.

Verdict: a structurally demanding industry where AXSM occupies favorable niches — not a structurally easy one. CNS offers huge prevalence, chronic use, ~92% gross margins, and real unmet need (especially AD agitation), but it is permanently anchored by cheap generics, gated by payers, exposed to IRA price-setting, and littered with clinical failures. It is a good industry only if you hold a protected, genuinely differentiated asset — which AXSM does, for now. The recent wave of competitor Phase 3 failures is a near-term supply-side positive in Marathon capital-cycle terms; the long-term reality is that an $8B peak narrative is exactly what attracts the next wave of capital and off-label/generic substitution.

4. Competitive Position

Moat type (Greenwald taxonomy): INTANGIBLES (patents + FDA exclusivity), with an emerging SCALE/DISTRIBUTION advantage (the CNS commercial engine). No network effects. Weak-to-moderate switching costs (prescribing habit and patient-stabilization inertia, not contractual lock-in).

The IP estate is real and unusually long-dated (FACT — the key positive). This is what separates AXSM from the typical reformulation play:

• Auvelity: ~130 patents. The invention is metabolic/pharmacokinetic — bupropion acts as a CYP2D6 inhibitor to raise and stabilize dextromethorphan plasma levels (a formulation/PK invention over two ancient generics). Teva filed a Paragraph IV ANDA in 2023; Axsome settled in February 2025, licensing Teva to launch a generic no earlier than September 30, 2038 (or March 31, 2039 with pediatric exclusivity) — a ~12–13-year protected runway (BioSpace settlement release).
• Sunosi: compound patent to ~2031, dose-escalation patent to 2038; Axsome settled all litigation with five generic filers in June 2026, setting generic entry no earlier than March 1, 2040 (BioSpace 2026).
• Symbravo: combination/formulation patents (protected; LOE less material given the tiny base). Note an Apotex Paragraph IV challenge filed Aug 2025, now in litigation.

So this is emphatically not a near-term cliff story — a genuine differentiator from cautionary CNS reformulators like Supernus, whose Trokendi/Oxtellar patents lapsed and forced perpetual pipeline churn.

But pressure-test the moat honestly (INTERPRETATION).

1. The active molecules are individually generic. Dextromethorphan, bupropion, solriamfetol’s building blocks, meloxicam, rizatriptan — all long-available. The moat is 100% the combination/formulation patent + label + brand/commercial machine, not molecular novelty. This creates a permanent “poor-man’s-Auvelity” substitution risk: physicians can prescribe generic DXM + generic bupropion off-label, and payers know it. The entire $8B Auvelity peak thesis is a bet that Axsome can defend a brand-price premium over two generics through label, data, DTC, and access — a marketing/access construct, not an unassailable franchise.
2. No switching costs or network effects. Nothing locks a prescriber or patient in beyond inertia. Contrast Jazz’s Xywav, whose REMS-controlled distribution is a real regulatory lock — Sunosi has nothing comparable.
3. Incumbent competition in the growth indications. In agitation, Rexulti has a ~3-year head start and an entrenched LTC/geriatric sales presence; Auvelity’s clean-label edge must be sold, patient by patient, against a cheaper (soon-generic aripiprazole-adjacent) incumbent. In migraine, AbbVie/Pfizer gepants dominate with vastly larger firepower.
4. IRA truncates the tail (~2032–33 on Auvelity) before the patent tail (2038–39).

Versus peers. Neurocrine (NBIX) is the closest analog — Ingrezza (VMAT2) is likewise a formulation/patent-plus-commercial-engine moat, blockbuster, single-product-concentrated, with ROIC roughly at WACC; AXSM is NBIX one cycle earlier and less profitable. Jazz (JAZZ) shows what a genuinely durable CNS moat looks like (oxybate REMS lock-in plus diversified oncology) — AXSM’s is weaker in kind. Supernus (SUPN) is the cautionary tale of the reformulation model played forward into cliffs.

Verdict: a REAL but SHALLOW moat — a portfolio of long-dated, time-limited patent monopolies over generically-available molecules, backstopped by an increasingly capable CNS launch/commercial engine. The durability is unusually long (LOE 2038–40, IRA ~2032–33) — better than the typical reformulation play — but it is durable in duration, not in kind: no network effects, no switching-cost lock-in, and economic value that rests on defending brand pricing over cheap generics through commercialization. The one genuinely compounding asset being built is the CNS commercial platform itself — the salesforce, payer relationships, DTC engine, and launch playbook. That, more than any single patent, is what could make AXSM a durable multi-product franchise rather than a serial single-drug patent-cliff company. Say it plainly: this is a launch-machine-plus-patents moat, not a franchise moat.

5. Growth History and Forward Opportunities

Historical ramp (FACT). $0 (2021) → $50.0M (2022) → $270.6M (2023) → $385.7M (2024) → $638.5M (2025, +65.5%); Q1-26 $191.2M (+57% YoY). This is all-organic, launch-driven growth — no acquisitions inflating the top line (Sunosi was bought but is a small, slow grower). Auvelity alone: $507.1M FY25 (+74% in its third full year), $153.2M Q1-26 (+59%). A psychiatry brand still compounding ~60–75% in years 3–4 is high-quality and rare.

The demand signal beneath the revenue is strong. In Q1-26 Auvelity generated 223,000 prescriptions (+35% YoY) against an antidepressant market growing just +1%. First-line/first-switch use rose to 56% of demand (a healthy sign that Auvelity is moving up the treatment algorithm, not stuck in refractory patients), and primary-care adoption reached 35% of prescribers. This is real, accelerating demand, not channel-stuffing.

Product-level dynamics.

• Auvelity is the engine — MDD scripts still ramping fast, now with the agitation TAM layered on (launch June 2026). This is the growth story.
• Sunosi grows steadily at +32–34% (faster under Axsome than under Jazz), with label expansions (MDD, ADHD, shift-work FOCUS-3 dosed June 2026, binge-eating) pursued to extend it. Peak framed $300–500M.
• Symbravo is early and tiny ($6.6M FY25, $4.1M Q1-26 but +36% QoQ on scripts), premium-priced into a gepant-dominated field. Its launch success is unproven; the $500M–$1B peak framing is aggressive.

Forward catalysts / TAM expansion (FACT). The agitation approval (Apr 30, 2026) is the headline; secondary legs include AXS-12 (narcolepsy/cataplexy NDA submitted), AXS-14 (fibromyalgia Phase 3), the solriamfetol expansions, smoking cessation, and the newer epilepsy (GABA-A) and schizophrenia/Tourette (PDE10A) assets. The pipeline is a coherent stack of shots on goal against the same commercial platform.

Management peak-sales framing (HYPOTHESIS — management commentary, not evidence). Post-approval, management raised Auvelity peak-sales guidance to “at least $8B,” roughly equally split MDD/agitation (up from a prior $2.5–6B), and frames Sunosi at $300–500M and Symbravo at $500M–$1B (FiercePharma, Seeking Alpha, 2026-04-30). Heavily discount these. The $8B Auvelity figure implies ~16x the FY25 base and rests on (a) full agitation conversion against entrenched Rexulti, (b) sustained MDD share gains, © defending brand pricing over generic components, and (d) doing all of it before IRA price-setting (~2032–33) truncates the tail. The direction (large, real TAM expansion) is right; the magnitude is a promotional stretch.

The honest caveat: growth is being bought. SG&A jumped to ~$185M in Q1-26 (salesforce doubling + heavy DTC); FY25 operating loss was −$169.2M; the company still burns cash (FCF −$93.9M FY25, narrowing), and SBC (~$93.8M FY25) roughly equals the cash burn. The open question is not whether Auvelity grows — it is whether it grows into the valuation while margins convert.

Verdict: HIGH-QUALITY growth in composition — organic, launch-driven, recurring script revenue, real TAM expansion from a genuine first/only non-antipsychotic agitation label — but priced for management’s aggressive peak-sales narrative. Among the best-executing CNS launches of the cycle; the risk is not whether Auvelity grows but whether it grows into an EV of ~$12.3B against generic substitution, entrenched incumbents, a doubling cost base, and an IRA-capped tail.

6. Financial Quality

Revenue and gross economics — excellent. Gross margin has held ~90–93% throughout the ramp (FY25 92.6%; Q1-26 92.3%). This is the good news and the bull’s foundation: at ~92% gross margin, every incremental dollar of Auvelity revenue drops enormous contribution once the fixed commercial base is covered. The operating-leverage math is compelling — it is the timing that is contested.

Operating losses and the cost base — the contested part. FY25 total opex was $805.3M on $638.5M revenue: cost of revenue $47.5M, R&D $183.3M (28.7% of revenue), and SG&A $570.6M — 89.4% of revenue. That SG&A ratio is the defining financial fact of the company: Axsome is pouring cash into DTC and salesforce for effectively four simultaneous launches (Auvelity MDD, Auvelity agitation, Sunosi expansion, Symbravo). FY25 operating loss was −$169.2M. Crucially, the trend did not simply improve into 2025 and then inflect to profit — Q1-26 SG&A jumped to ~$185M and the operating loss re-widened to −$62.8M (from −$36.0M in Q4-25) as agitation-prelaunch spend loaded in. GAAP breakeven is being pushed out, not pulled in, in the near term.

Quarterly operating loss trajectory ($M): Q1-25 −55.5, Q2-25 −44.8, Q3-25 −32.9, Q4-25 −36.0, Q1-26 −62.8. The 2025 narrowing was real; the Q1-26 re-widening is the launch-spend reality check.

Cash flow and SBC — the burn is paid in stock. FY25 CFO was −$93.4M and FCF −$93.9M (both narrowing from −$145M / −$146M in FY23). But stock-based compensation of $93.8M (14.7% of revenue) roughly equals the entire FY25 cash burn. In other words, the company is approximately operating-cash-neutral before SBC — the burn is effectively being financed by ~$94M/year of dilution rather than cash out the door. This is high but sector-normal; it is the primary reason the share count grinds ~8%/year higher and it should be treated as a real, recurring economic expense, not a “non-cash” footnote.

Balance sheet — adequate, well-structured. Q1-26 (2026-03-31): cash $305.1M; debt ~$188M gross (a $70M revolver + $117.85M term loan) plus ~$32M finance leases; net cash ~$117M ex-leases. The term facility is a Blackstone loan (May 2025, up to $570M) — details below. Current ratio 1.39. Total equity is only $54.6M against a −$1.37B accumulated deficit — hence a ~$1/share book value that renders P/B meaningless (229x/93rd percentile is noise for an R&D-expensing pharma). Management states the current cash balance is “sufficient to fund operations into cash-flow positivity” without a further raise — plausible given ~$117M net cash, $180M of undrawn term capacity, and a $200M accordion, but contingent on the launch-spend curve behaving.

Quality-of-earnings flags (normalize before valuation). (1) FY24 net loss was inflated by a +$28.1M charge for change in fair value of contingent consideration (the Jazz/SK Sunosi royalty liability); FY25 booked a −$2.5M gain on the same line — this non-cash swing accounts for a large chunk of the apparent FY24→FY25 loss improvement. (2) FY25 carried a $10.4M debt-extinguishment loss (Blackstone refi, one-time). (3) Vendor-reported “non-operating income” figures (e.g., a +$14.3M Q3-25 item) do not reconcile to the filed GAAP statements and are almost certainly the contingent-consideration remeasurement reclassified below the line by data aggregators — a non-cash accounting swing, not operating income. Do not treat any of these as recurring earnings.

Returns. ROIC/ROE are negative and not yet meaningful — the company has never earned a GAAP profit. This is a pre-profitability growth story; the relevant question is the forward steady-state return structure, not a trailing ROIC.

Verdict: the gross economics are genuinely excellent (~92% margin) and the balance sheet is adequately funded, but this is still a cash-burning, loss-making, ~8%/year-dilutive company whose defining metric — SG&A at ~89% of revenue — is heading the wrong way in the near term as the agitation launch loads in. Economics should improve dramatically with scale given the gross margin; the evidence that they are improving is, for now, deferred. The economics-improve-with-scale thesis is credible but unproven — and Q1-26 is a caution, not a confirmation.

7. Capital Allocation

For a pre-profit biotech, “capital allocation” means how the burn has been funded and how capital has been deployed. On both, Axsome scores better than the sector norm — with two governance asterisks.

Financing — debt-led, and dilution is moderate. Over ~4.25 years, shares grew 37.6M → 51.4M (~+37%, ~8%/year) — moderate for a biotech that scaled revenue from ~$0 to $638M. There has been exactly one large secondary (June 2023: 3.0M shares at $75 = $225M gross), a small ATM (~$53M in FY25), and option/ESPP proceeds (~$60M FY25). Management has leaned on debt rather than equity: in May 2025 it refinanced the 2020 Hercules loan into a Blackstone facility of up to $570M ($120M term funded at close + $180M delayed-draw + $70M revolver + $200M accordion), at Term SOFR + 4.75% (~9.58% effective), maturing May 2030, first lien, with a $30M minimum-liquidity covenant. At ~9.6% this is cheap versus issuing equity at a $12B valuation, leverage is trivial against the cap, and ~$380M of undrawn term + accordion capacity funds the launches without a raise. This is competent, non-dilutive balance-sheet management.

M&A / business development — capital-light and largely accretive. The Sunosi US-rights acquisition from Jazz (May 2022, ~$53M upfront, plus a high-single-digit royalty to Jazz and assumed SK/Aerial obligations including up to $162.5M in revenue milestones) added a third marketed product and >$100M of revenue — a cheap, sensible tuck-in. The AXS-17 (AZD7325) epilepsy license from AstraZeneca (Nov 2025) added a de-risked (>700-patient) pipeline option at low cost (terms undisclosed — OPEN QUESTION).

The two governance asterisks.

1. A perpetual related-party royalty to the CEO. Auvelity and the other core candidates were licensed in 2012 from Antecip Bioventures II LLC, an entity owned by CEO Herriot Tabuteau. Axsome pays Antecip a perpetual 3.0% royalty on Auvelity net sales — $15.2M in FY25 (up from $8.7M FY24) and rising with the drug. The CEO personally collects a growing, perpetual royalty on the company’s flagship product. It is disclosed and contractually old, but it is a permanent leakage of shareholder economics to the CEO and should be named as such. (Separately, Antecip Capital LLC holds 13.4% of the stock.)
2. SBC-driven dilution is the true cost of the burn. ~$94M FY25 SBC ≈ the year’s cash burn, driving the ~8%/year share creep. Real, recurring, and easy to under-weight because it is “non-cash.”

Executive comp and alignment — reasonable. CEO total comp was $10.28M (2025), flat YoY, heavily equity-weighted (base $835K, no cash bonus). 2025 PSUs vest over three years, 50% on a 3-year revenue goal and 50% on clinical/regulatory milestones — sensible long-term metrics that reduce the risk of rewarding pure share-price momentum. Tabuteau beneficially owns 16.4% (~$2.2B at $244) — very large skin in the game; all directors/officers own 20.6%.

But the insider tape is one-directional (important for judgment). Every reviewed 2026 Form 4 is a Rule 10b5-1 planned exercise-and-sell of deep-in-the-money legacy options; there is not a single open-market purchase (code P) in the corpus. Tabuteau exercised-and-sold ~99,300 shares for ~$23.9M across June/July 2026 tranches (~$240–241); CFO Pizzie ~$7.9M; the COO and directors have been selling since February (starting ~$161, capturing the run to ~$249). It is routine, planned diversification — the CEO is monetizing a small slice and still holds ~16.4% — so it is not a strong conviction signal either way. But the read for judgment is clean: management is a persistent net seller at/near all-time highs, with zero offsetting conviction buying.

Verdict: reasonably good stewardship for a commercial-stage biotech — debt-led, non-dilutive financing, cheap accretive BD, sensible equity-weighted comp — with two asterisks: ~8%/year SBC dilution and a perpetual related-party royalty flowing to the CEO. This is a reinvest-everything story, not a capital-return one — appropriate given the runway — but investors are funding the launch machine while insiders sell into it.

8. Changes and Headwinds — Last Two Years

Developments that strengthen the thesis.

• Auvelity approved for Alzheimer’s-disease agitation (Apr 30, 2026) — the sNDA succeeded, opening a large new indication where only Rexulti (an antipsychotic with a boxed mortality warning) is otherwise approved. The single biggest positive catalyst of the period; converts the swing factor from a binary regulatory event to a commercial-uptake question.
• Symbravo approved (Jan 2025) and launched (Jun 2025) — a third commercial product and an added growth leg.
• Revenue $638.5M FY25 (+66%); Q1-26 +57%; gross margin ~92%; cash burn narrowing on a full-year basis.
• Litigation de-risking: Teva/Auvelity settled (Feb 2025); all Sunosi ANDA litigation settled (Alkem Feb 2026; remainder June 2026). Removes near-term generic-timing uncertainty on both flagships and locks in the 2038–40 exclusivity runways.

Developments that weaken it / genuine headwinds.

• The agitation clinical package was mixed. The ACCORD-1 relapse-prevention trial hit (HR 0.275, p=0.014), but the ADVANCE-2 Phase 3 FAILED its primary endpoint (no separation from placebo at Week 5). Approval came despite one failed pivotal — which raises real questions about effect size, label scope, and how the drug performs against Rexulti in the real world.
• SG&A explosion (~89% of revenue; Q1-26 ~$185M) pushed the operating loss back to −$62.8M and delays GAAP breakeven.
• Generic/IP overhang persists: an Apotex Paragraph IV challenge on Symbravo (Aug 2025) is in litigation, and the Teva settlement — while favorable — confirms a defined (2038/2039) generic-entry date on Auvelity.
• An ongoing securities class action (In re Axsome Therapeutics Securities Litigation, SDNY) over AXS-07/Symbravo CMC disclosures partially survived a motion to dismiss (granted-in-part/denied-in-part, Mar 31, 2025) and remains pending — a modest but real overhang.
• IRA pricing: Auvelity’s ~2032–33 Medicare-negotiation exposure is long-dated but real.

Verdict: net strengthens the thesis. The agitation approval and Symbravo launch add two growth legs; the ANDA settlements remove overhangs and lock in long exclusivity. Against that, the failed ADVANCE-2 pivotal, the SG&A-driven delay to profitability, the pending securities suit, and the Symbravo generic challenge are real but manageable. The tension is valuation and timing, not franchise deterioration.

9. Risk Analysis

The dominant risks are valuation (#1) and agitation-launch execution (#2) — both of which bear directly on the price, not the survival, of the business. Catastrophic loss is low: this is a funded, de-risked, revenue-generating company, not a binary clinical bet.

10. Valuation Discussion (Embedded Expectations)

The setup. AXSM is an unprofitable, ~92%-gross-margin specialty-CNS pharma at EV ~$12.3B on TTM revenue ~$708M → ~17.4x EV/TTM sales. On forward numbers (2026E revenue ~$0.9–1.0B if ~40–50% growth holds; 2027E ~$1.3–1.5B), that is ~12–13x 2026E and ~8–9x 2027E sales — still a multiple of the peer set. GAAP EPS is negative, so P/E is N/A; the entire valuation is a discounted claim on a future franchise. On AZI’s own-history percentiles, AXSM sits at the 80.8th composite / 68th P/S — rich, but well short of the 2022 ~60x EV/Sales extreme (revenue has grown into the multiple). The record here is the price, not the multiple.

Sector comps (EV/Sales anchors the premium). (EV via ROIC, TTM to 2026-03-31.)

Read: AXSM trades at ~5–6x the peer-median EV/Sales. That gap is entirely a bet on (i) growth (57% vs peers’ single-digit-to-mid-teens) and (ii) future conversion to NBIX/JAZZ-like ~15x EV/EBIT economics. Valued like NBIX today (~4x sales), EV would be ~$2.8B — so ~77% of the current EV is franchise-not-yet-built optionality.

Reverse-DCF / embedded expectations — what must be true. Frame the $12.3B EV as a discounted claim on a mature specialty-pharma earnings stream. Assumptions (ASSUMPTION unless noted): steady-state operating margin ~33% (NBIX/JAZZ-like once launch/DTC intensity normalizes), ~18% cash tax (NOLs bleed off), exit multiple ~13–15x NOPAT (specialty pharma with patent-cliff risk rarely sustains >15x), discount ~11% (single-therapeutic-class concentration, catalyst risk), maturity ~5 years out (≈2031).

• Present EV $12.3B ≈ (14x × NOPAT₂₀₃₁) × 0.593 (11%/5yr) → required NOPAT₂₀₃₁ ≈ $1.48B → EBIT ≈ $1.8–2.0B → steady-state revenue ≈ $5.5–6.0B at 33% margins.
• Cross-check via forward sales: to justify today’s EV at even a 4x “mature” multiple with room to spare (a second NBIX-style re-rate should not be assumed), the market is effectively underwriting ~$4.5–5.5B of durable franchise revenue realized within ~5 years — roughly 7x the current run-rate, or ~55–70% of management’s $8B Auvelity-alone peak claim spread across the whole portfolio.

Scenario framing (peak-sales building blocks; ASSUMPTION/INTERP):

What the market is pricing correctly vs aggressively. Correctly: AXSM is now a genuine multi-product CNS franchise with an approved blockbuster path (MDD + a large newly-approved agitation market whose only branded rival carries a boxed mortality warning), 57% growth, ~92% gross margins, and near-cash-breakeven ex-SBC — a premium to sleepy peers is warranted. Aggressively: the pace of margin conversion (Q1-26 losses widened), the durability of a moat built on two old molecules, single-therapeutic-class concentration, and near-flawless agitation uptake against entrenched Rexulti. The stock trades above the ~$235 average sell-side PT — the market has out-run even a Strong-Buy consensus. (No price target; embedded-expectations framing only.)

Verdict: the current price underwrites the base-to-bull case and offers little margin of safety on the base case. At ~17.4x trailing sales, the market is paying today for a franchise that must be built over five years against real execution and IP risk. The valuation is not indefensible — the base case is roughly fair — but it embeds success, not optionality on success.

11. Variant Perception

Consensus. Sell-side is overtly bullish — roughly a Strong-Buy composite (≈18 Buy / 1 Hold / 0 Sell); TD Cowen raised its PT to $300 (June 17, 2026). Tellingly, the average PT (~$235) sits at or below the $244 spot — the stock has run past the consensus, so the residual bull case now lives almost entirely in pipeline/peak-sales optionality, not current-model upside.

Strongest bull case. A CNS franchise compounder: Auvelity ramping fast in MDD, now with a second large indication (agitation, $8B management peak claim), Symbravo and Sunosi adding breadth, and a stacked pipeline (AXS-12 narcolepsy NDA, AXS-14 fibromyalgia, solriamfetol expansions, epilepsy and schizophrenia assets). ~92% gross margins mean violent operating leverage once launch spend normalizes → a clear path to profitability and, as a de-risked single-asset-turned-franchise with net cash, a plausible large-pharma takeout target. The competitive set just thinned (aticaprant, navacaprant failures). Momentum is on the bull’s side.

Strongest bear case. The price already discounts pipeline success and no generics. SBC (~$94M) ≈ cash burn; shares 37.6M → 51.4M since 2021; Auvelity is two old molecules with litigable combination patents; ~80% single-class concentration; the agitation package included a failed pivotal (ADVANCE-2) and must out-execute entrenched Rexulti in a hard-to-serve LTC-heavy market; and operating losses are widening near-term. Any two-to-three quarters of decelerating Auvelity TRx or a soft agitation launch de-rates a stock priced for a 60–70% realization of an $8B claim at an ATH.

The 3–5 assumptions that matter most (and what falsifies each):

Factor / positioning read (is this a crowded momentum long?). Low market beta (0.70) and R²~20% mean AXSM is idiosyncratic and catalyst-driven, not macro-sensitive — it moves on FDA/print events, not the tape (positive alpha 0.29). But the momentum is extreme: RS-12m +137%, near the ATH (−4.3%), y1 return +135% (Sharpe 3.19), and its factor-similar cohort is a high-beta growth-biotech basket (DNLI, IDYA, ATAI, ARKK). It screens as a momentum/growth-biotech name despite its own low beta. Assessment (INTERP): yes, this reads as a crowded, priced-for-perfection momentum long — Strong-Buy consensus, spot above the average PT, near-ATH, growth-biotech cohort, and a valuation that needs ~7x revenue growth to steady-state. The risk is binary and company-specific (the next TRx prints and the agitation curve), and the historical downside skew is real — the same name carried a 10-year max drawdown of −81% and fell ~70% in 2021 on a single FDA letter. Consensus is offside if agitation uptake merely meets rather than beats expectations, because “meets” is already embedded in an ATH price.

12. Fact vs. Interpretation Table

13. Open Questions

1. Real-world agitation uptake vs Rexulti — the H2-26 launch curve is the single most important unknown; no hard scripts yet.
2. Can Axsome defend Auvelity brand pricing against “poor-man’s-Auvelity” generic DXM+bupropion substitution and payer step-edits at scale?
3. Profit inflection timing — is FY26 the trough of losses, or does the agitation launch push breakeven past 2027?
4. Symbravo credibility — is even a $500M peak realistic in a gepant-dominated, cost-flagged field? The launch is tiny so far.
5. Exact IRA selection year and magnitude for Auvelity (~2032–33 estimate).
6. AXS-17 and other BD terms — undisclosed upfront/milestone/royalty economics.
7. Why did ADVANCE-2 fail while ACCORD-1 hit, and what does that imply about agitation effect size and label scope in practice?

14. What Must Be True

Bull case — what must be true: Auvelity compounds into a multi-billion franchise across MDD and agitation (~$4.5–5.5B combined), the agitation launch tracks at or above Rexulti’s benchmark, gross margins convert to ~30–35% operating margins as launch spend normalizes and losses flip to profit within ~2–3 years, no early generic/IP breach occurs before the mid-2030s, and the pipeline delivers at least one more approved product to sustain the “franchise” narrative.

• Falsification test: two or three consecutive quarters of decelerating Auvelity TRx, or agitation scripts tracking below the Rexulti launch benchmark through H2-2026 — either would break the multi-billion-peak assumption on which ~77% of the EV rests. A widening (not narrowing) operating loss through 2027 would independently falsify the margin-conversion leg.

Bear case — what must be true: the ~$12.3B EV proves to embed a franchise that never fully materializes — agitation uptake is slow against entrenched Rexulti, brand pricing erodes to generic substitution/step-edits, SG&A stays elevated and profitability slips, and single-class concentration plus IRA truncation caps the tail — so the stock de-rates toward peer multiples as growth normalizes.

• Falsification test: Auvelity + agitation TRx accelerating through 2026–27 with the operating margin visibly inflecting toward profit, and a second pipeline product approved — that combination would validate the franchise and refute the “one drug, priced for perfection” bear.

15. Source Appendix

See Appendix B — Source Appendix in the combined report for the full source list (primary filings, FDA/company releases, transcripts, and third-party data), with URLs and access dates. Primary sources (SEC filings, FDA/company press releases, earnings-call transcripts) are prioritized over secondary; management commentary is treated as hypothesis and validated against filings and external evidence throughout.

APPENDIX A — Standard Diligence Questionnaire

Axsome Therapeutics, Inc. (NASDAQ: AXSM) — Report date 2026-07-04

Supplemental to the memo. Fact / Interpretation / Assumption labels applied where they matter.

General

What thoughtful questions have other investors asked? (1) Can Auvelity defend a brand-price premium over generic dextromethorphan + generic bupropion? (2) How large is the Alzheimer’s-agitation opportunity in practice against entrenched Rexulti, given ADVANCE-2 failed? (3) When does the company turn GAAP-profitable, and does the agitation launch push that out? (4) How real is the $8B Auvelity peak claim? (5) Is AXSM a takeout candidate, and at what premium? (6) How much of the equity value is one drug?

Cyclicality & Earnings Nature

• Cyclical high or low? Neither — AXSM is early in a secular launch ramp, not a cycle. Earnings are below normal (still loss-making) because the company is in peak-investment mode (SG&A ~89% of revenue). (Interpretation.)
• External environment or internal actions? Internal — revenue is driven by launch execution (salesforce, DTC, formulary wins), not macro. Low market beta (0.70), R²~20% confirm idiosyncratic, catalyst-driven behavior. (Fact/Interpretation.)
• Revenue stability? Recurring, chronic-use maintenance scripts (antidepressants, wake-promoting agents) → stable and refilling once patients stabilize, but exposed to payer step-edits and generic substitution. (Interpretation.)
• Product/market outlook? MDD (large, generic-anchored), AD agitation (large, underserved, growing ~7–8%), EDS (crowded), migraine (crowded, gepant-dominated). Growing markets; AXSM’s slice depends on defending differentiation. Domestic (US); some ex-US Sunosi royalties. (Fact.)

Business Quality & Competitive Moat

• Industry more or less competitive? MDD competition thinned (aticaprant, navacaprant Phase 3 failures); agitation and migraine remain competitive (Rexulti; AbbVie/Pfizer gepants). (Fact.)
• How profitable is the business? Gross margin ~92% (excellent); operating and net margins negative (not yet profitable). ROIC/ROE negative and not meaningful. (Fact.)
• How profitable is the industry / barriers to entry? Branded CNS is highly profitable while patent-protected; barriers are patent + FDA exclusivity (long-dated here: 2038–40) plus commercial scale — but zero once molecules go generic. (Interpretation.)
• Easily understood? Yes — three marketed drugs, script-driven revenue, transparent P&L. (Fact.)
• Undermined by foreign low-cost labor? No — pharma; risk is domestic generic substitution and IRA price-setting, not offshoring. (Fact.)
• Do brands matter? Yes, critically — the entire moat over generic components is the brand + label + data + commercial push. (Interpretation.)
• Nature of competition? Clinical differentiation, formulary access, DTC, salesforce reach. (Fact.)
• Switching costs? Low — prescriber habit and patient-stabilization inertia only; no contractual lock-in. (Interpretation.)

Financial Condition & Balance Sheet

• Assets not on the balance sheet? The commercial platform (salesforce, payer relationships, DTC engine, prescriber base) and the IP/brand value are not capitalized — arguably the most valuable assets. (Interpretation.)
• Off-balance-sheet liabilities? Royalty obligations (3.0% perpetual to CEO’s Antecip on Auvelity; high-single-digit to Jazz on Sunosi; SK/Aerial milestones up to $162.5M); operating/finance leases (~$32M). (Fact.)
• Accounting conservatism? Reasonable; watch the non-cash contingent-consideration fair-value swings (+$28.1M FY24 charge, −$2.5M FY25 gain) and the $10.4M one-time debt-extinguishment loss. R&D fully expensed. (Fact.)
• CapEx-hungry? No — asset-light; FY25 capex only $0.5M. The “capex” is really SG&A/DTC (expensed). (Fact.)

Capital Allocation & Management

• FCF generation and use? Negative FCF (−$93.9M FY25, narrowing); all capital reinvested into launches. No dividend, no buyback (appropriate at this stage). (Fact.)
• Significant acquisitions? Sunosi US rights from Jazz (~$53M, 2022); AXS-17 epilepsy license from AstraZeneca (Nov 2025, terms undisclosed). Both capital-light. (Fact.)
• Buying back shares? No — share count growing ~8%/yr on SBC + option exercises. (Fact.)
• Issuing shares to insiders? SBC ~$94M FY25 (14.7% of revenue); insiders exercise low-strike legacy options and sell. (Fact.)
• Compensation policy? CEO $10.3M, equity-heavy, PSUs on 3-yr revenue + clinical/regulatory metrics; reasonable. (Fact.)
• Management motivations? Founder-CEO owns 16.4% (~$2.2B) — large alignment — but collects a perpetual 3.0% Auvelity royalty via Antecip and is a persistent 10b5-1 net seller near ATH with zero open-market buys. (Fact/Interpretation.)

Valuation & Market Data

• ADR / MLP / K-1? No — US common stock, standard 1099. (Fact.)
• Dividend policy? None. (Fact.)
• How profitable? Not yet — negative net income; ~92% gross margin. (Fact.)
• Net income vs cash from operations diverging? Yes, favorably — net loss −$183M FY25 vs CFO −$93M, the gap is largely SBC (~$94M) and working-capital timing. Ex-SBC the company is near operating-cash-neutral. (Fact/Interpretation.)

Risks & Downside

• What causes the stock to decline? Decelerating Auvelity TRx, soft agitation launch, a pipeline Phase 3 miss/CRL, an IP/generic breach, or simple multiple compression from a priced-for-perfection ATH. (Interpretation.)
• Catastrophic loss risk? Low — three approved products, ~$117M net cash, funded to breakeven; not a binary clinical bet. (Interpretation.)
• Total loss? Very low — de-risked, revenue-generating, net-cash company. (Interpretation.)

Recent News & Events

• Environment changed recently? Yes, materially positive — Auvelity approved for Alzheimer’s agitation (Apr 30, 2026), $8B peak guidance, June launch; all Sunosi ANDA litigation settled (2026). (Fact.)
• Significant acquisitions / accounting changes? AXS-17 epilepsy license (Nov 2025); Blackstone $570M debt refinance (May 2025, one-time $10.4M extinguishment loss). No adverse accounting-policy changes. (Fact.)
• Recent changes — markets/facilities/management? New indication (dementia/geriatric care), salesforce doubling to ~630 reps, national DTC campaign; management team stable (Tabuteau/Pizzie/Maizel/Jacobson). (Fact.)

APPENDIX B — Source Appendix

Axsome Therapeutics, Inc. (NASDAQ: AXSM) — Report date 2026-07-04

Primary sources prioritized over secondary. Management commentary treated as hypothesis and validated against filings and external evidence. All URLs accessed 2026-07-04 unless noted.

Primary — SEC filings (EDGAR, CIK 0001579428)

• FY2025 Form 10-K (filed 2026-02-23, period 2025-12-31) — financials, segment/product detail, IP/litigation, related-party (Antecip) disclosures, Blackstone loan terms, comp. Mirrored: output/AXSM/sources/10-K/.
• Form 10-Q Q1-2026 (period 2026-03-31) — balance sheet, product splits, opex. Mirrored: output/AXSM/sources/10-Q/.
• DEF 14A proxy (2026-04-24) — executive compensation, PSU metrics, beneficial ownership (Tabuteau 16.4%; Antecip Capital 13.4%), related-party royalty. Mirrored: output/AXSM/sources/DEF_14A/.
• 8-K material events: Symbravo approval (~Jan 2025); Blackstone $570M facility (2025-05-08); Auvelity Alzheimer’s-agitation approval (2026-04-30, Item 8.01); Q1-26 results (2026-05-04); Sunosi litigation settlement (2026-06-03). Mirrored: output/AXSM/sources/8-K/.
• Form 4 corpus (2025–2026) — insider transactions (all 10b5-1 exercise-and-sell; zero open-market buys). Via scripts/edgar.sh filings AXSM 4 / EDGAR ownership XML.

Primary — company & FDA releases / transcripts

• Axsome FY2025 results, GlobeNewswire, 2026-02-23.
• Axsome Q1-2026 results, 2026-05-04; and Q1-2026 earnings-call transcript (ROIC get_latest_earnings_call, 2026-05-04) — Auvelity $8B peak guidance, 223k Rx, coverage 86%, “into cash-flow positivity,” product splits.
• Auvelity Alzheimer’s-agitation FDA approval, Axsome PR (GlobeNewswire), 2026-04-30: https://www.globenewswire.com/news-release/2026/04/30/3285345/33090/en/axsome-therapeutics-announces-fda-approval-of-auvelity-dextromethorphan-hbr-and-bupropion-hcl-for-the-treatment-of-agitation-associated-with-dementia-due-to-alzheimer-s-disease.html
• Axsome Q3-2025 results, GlobeNewswire, 2025-11-03 (coverage, GPO contracting).
• Teva/Auvelity patent-litigation settlement (generic no earlier than Sep-30-2038 / Mar-31-2039), BioSpace: https://www.biospace.com/press-releases/axsome-therapeutics-announces-settlement-agreement-resolving-auvelity-dextromethorphan-hbr-bupropion-hcl-patent-litigation
• Sunosi (solriamfetol) patent-litigation settlement (generic no earlier than Mar-1-2040), BioSpace, 2026.
• Axsome historical earnings-call transcripts, Q2-2022 through Q4-2023 (company IR / public transcript archives): Sunosi acquisition close (2022-05-09), AXS-07 CRL/resubmission, ADVANCE/ACCORD agitation trials, 2023 combined Auvelity+Sunosi revenue ~$205M.

Secondary — industry, competitive, regulatory

• FDA approves Auvelity for AD agitation, Psychiatric Times / NeurologyLive, 2026-04-30.
• Auvelity peak-sales raised to $8B, FiercePharma, 2026-04-30: https://www.fiercepharma.com/pharma/after-alzheimers-agitation-nod-axsome-jacks-auvelitys-peak-sales-projection-8b ; Seeking Alpha, 2026-04-30.
• J&J aticaprant Phase 3 failure, pharmaphorum, 2025: https://pharmaphorum.com/news/one-jjs-blockbuster-depression-hopes-has-flamed-out
• Neumora navacaprant 0-for-3 Phase 3, TechTimes, 2026-06-16: https://www.techtimes.com/articles/318502/20260616/kappa-opioid-antidepressant-navacaprant-goes-0-3-phase-3-neumora-cuts-35-staff.htm
• Migraine drugs market size, Grand View Research: https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market
• Rexulti / brexpiprazole AD-agitation approval (May 2023) and market data; narcolepsy/EDS market sizing (industry reports).
• Salesforce expansion to ~600 reps, Seeking Alpha, 2026: https://seekingalpha.com/news/4555319-axsome-signals-auvelity-sales-force-expansion-to-600-reps-ahead-of-potential-alzheimer-s
• Sell-side: TD Cowen PT $300 (2026-06-17, GuruFocus/StreetInsider); average PT ~$235 (TipRanks/MarketScreener).

Quantitative data providers (reconciled to filings)

• ROIC.ai MCP — income statement, balance sheet, cash flow, enterprise value, valuation multiples, profitability ratios, company profile, transcripts (AXSM + peers NBIX/JAZZ/SUPN/ACAD/PCRX/BIIB), accessed 2026-07-04.
• AZI — 5-year adjusted price CSV (https://azitrading.com/controls/download-data.php?t=AXSM); fundamentals valuation_index own-history percentiles (composite 80.8th, P/S 68th).
• FactorsToday — stock-loadings, leaderboard, stock-info, related-stocks (beta 0.70, R²~20%, RS-12m 137%, cohort DNLI/IDYA/ATAI/ARKK), accessed 2026-07-04.
• SEC EDGAR XBRL (scripts/edgar.sh) — authoritative US-filer facts and filing index.

Note: third-party aggregated data (ROIC, AZI, FactorsToday) is not primary; every material number was reconciled to the underlying SEC filing or company release. Where vendor “non-operating income” figures did not reconcile to GAAP statements, the filing controls (see the Financial Quality quality-of-earnings flags).